Citations

Clear

40 citation(s) found for "Johnson, Stephen".

Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for stage III melanoma: outcomes and the impact of the microbiome from the NeoACTIVATE trial
Block, Matthew S. , Nelson, Garth D. , Chen, Jun , Johnson, Stephen , Yang, Lu , Flotte, Thomas J. , Grewal, Eric P. , McWilliams, Robert R. , Kottschade, Lisa A. , Domingo‐Musibay, Evidio , Montane, Heather N. , Hui, Jane Yuet Ching , Erskine, Courtney L. , Zahrieh, David , Flotte, Thomas James , Markovic, Svetomir , Dimou, Anastasios , Montane, Heather N , Piltin, Mara , Price, Daniel L , Khariwala, Samir S , Hui, Jane Yuet Ching , Erskine, Courtney L , Strand, Carrie A , Zahrieh, David , Dong, Haidong , Hieken, Tina J , McWilliams, Robert R , Chen, Jun , Grewal, Eric P , Johnson, Stephen , Markovic, Svetomir N. , Dimou, Anastasios , Piltin, Mara A. , Price, Daniel L. , Strand, Carrie , Dong, Haidong , Hieken, Tina J.

Mayo Clinic

Journal for ImmunoTherapy of Cancer | April 15, 2025 | Volume: 13 | Issue: 4 | Pages: e011706

10.1136/jitc-2025-011706 | PMID 40234093 Get It

Background Neoadjuvant treatment has become standard for patients with high-risk operable stage III melanoma, but the optimal regimen is unknown. Targeted therapy approaches yield high pathological response rates, while immunotherapy regimens show favorable recurrence-free survival (RFS). NeoACTIVATE was designed to address whether a neoadjuvant combination of both targeted therapy and immunotherapy might leverage the benefits of each. Methods We tested neoadjuvant treatment with 12 weeks of vemurafenib, cobimetinib, and atezolizumab for patients with BRAF-mutated (BRAFm) melanoma (cohort A) and cobimetinib and atezolizumab for patients with BRAF-wild-type (BRAFwt) melanoma (cohort B), regimens which we have shown generate a substantial major pathological response. After therapeutic lymph node dissection, patients received 24 weeks of adjuvant atezolizumab. Here, we report survival outcomes and their association with biomarkers assayed among the gut microbiome and peripheral blood immune subsets. Results With 49 months median follow-up, the median RFS was not reached for cohort A and was 40.8 months for cohort B. At 24 months after operation, 2 of 14 cohort A patients and 4 of 13 cohort B patients had experienced distant relapse. Key findings from correlative analyses included diversity, taxonomic and functional metagenomic gut microbiome signals associated with distant metastasis-free survival at 2 years. Notably, we observed a strong correlation between low microbial arginine biosynthesis (required for T-cell activation and effector function) and early distant recurrence (p=0.0005), which correlated with taxonomic differential abundance findings. Peripheral blood immune monitoring revealed increased double-positive (CD4+CD8+) T cells in patients with early recurrence. Conclusions Neoadjuvant treatment with cobimetinib and atezolizumab±vemurafenib was associated with a low rate of distant metastasis in patients with high-risk stage III melanoma. Freedom from early distant metastasis was highly associated with taxonomic differences in gut microbiome structure and with functional pathway alterations known to modulate T cell immunity. Identification of predictive biomarkers will permit optimization of neoadjuvant therapy regimens for individual patients. Trial registration number NCT03554083.
Corynebacterium mayonis sp. nov. isolated from a human blood culture
Mohammed, Hamidu T. , Koscianski, Christina, Berent, Taylor E. , Gordy, Garrett G. , Herren, Sebastian , Patel, Robin , Koscianski, Christina A, Herren, Sebastian C , Patel, Robin , Johnson, Stephen A.

Mayo Clinic

International Journal of Systematic and Evolutionary Microbiology | January 31, 2025 | Volume: 75 | Issue: 1 | Pages: No page available

10.1099/ijsem.0.006632 | PMID 39887037 Get It

A novel Corynebacterium species, strain BD556T, isolated from blood, was identified at Mayo Clinic, Rochester, MN, USA. After failing definitive identification using MALDI-ToF MS and partial 16S rRNA gene sequencing, BD556T was characterized using a polyphasic approach, including phenotypic, biochemical and whole-genome sequencing methods. BD556T was a Gram-positive rod with clubbed ends, facultatively anaerobic, catalase-positive, oxidase-negative and non-motile. Colonies were white, opaque and non-haemolytic with halo-like edges. BD556T grew at 35 °C in room air, with CO2 and under anaerobic conditions. BD556T grew well in 0 and 6% NaCl and weakly in 10% NaCl. The genome size was 2 349 779 bp with a G+C content of 60.39%. Phylogenetic analysis using 16S rRNA gene sequence analysis, average nucleotide identity and digital DNA–DNA hybridization between the genome of BD556T and the closest type strains from the Type Strain Genome Server database yielded separation values well beyond those required for species delineation. Chemotaxonomic analyses of BD556T revealed ribose, arabinose and galactose as whole-cell sugars and an A1γ meso-diaminopimelic acid-direct peptidoglycan type. The major cellular fatty acids were C15 : 0 (21.0%), C16 : 0 (14.8%), C17 : 1 ω9c (26.2%), C17 : 0 (13.3%) and C18 : 1 ω9c (18.3%). Polar lipids included diphosphatidylglycerol, phosphatidylglycerol and unidentified glycolipids and phospholipids. BD556T also contained mycolic acids (32–36 carbons) typical of corynebacteria. The respiratory quinones were dominated by MK-8(H2) (71.2%) and MK-9(H2) (25.9%), with smaller amounts of MK-7(H2) and MK-10(H2). The results presented support the tenet that BD556T (=TSD 427T=NCTC 15078T) is a novel species for which the name Corynebacterium mayonis sp. nov. is proposed.
APOE genotype modifies benefits of calorie restriction against aging
Chen, Yixing , Ren, Yingxue , Ikezu, Tadafumi C. , Pan, Meixia , Kashyap, Sonu , Bueser, Katrina Rae , Wetmore, Allison M, Kurti, Aishe, Meneses, Axel , Owens, Jada A., Chini, Eduardo N. , Chen, Jun, Qiao, Wenhui , Johnson, Stephen A. , Li, Fuyao , Chen, Kai , Owens, Jada A., Chen, Jun, Han, Xianlin , Bu, Guojun , Zhao, Na

Mayo Clinic

Alzheimer's & Dementia | January 3, 2025 | Volume: 20 | Issue: S1 | Pages: No page available

10.1002/alz.085702 Get It

AbstractBackgroundThe efficacy of Calorie Restriction (CR) in enhancing cognition, promoting healthy aging, and extending lifespan is well‐established. Yet, it remains unclear whether the apolipoprotein E (APOE) genotype, a known modifier for aging and age‐related disorders, influences the beneficial effects of CR in countering aging.MethodsTo investigate this question, we utilized humanized APOE mouse models, which express APOE2, APOE3, or APOE4 alleles systematically (refer to as E2, E3, and E4 mice). These mice were subjected to either ad libitum (AL) feeding or 30% CR feeding, starting from 12 months and continuing up to 20 months of age (N = 11‐20/ genotype /group, mixed sex). We monitored energy expenditure using the Comprehensive Laboratory Animal Monitoring System (CLAMS). Additionally, we evaluated anxiety levels and memory capabilities through various behavioral tests. Finally, we collected brain, blood, and feces samples for transcriptomic, lipidomic, and microbiomic analyses.ResultsCLAMS measurements showed that CR significantly decreased the metabolic rate in E3 and E4 mice, but not E2 mice, during the non‐feeding period of the CR group, compared to the AL group. Furthermore, CR reduced anxiety and enhanced associative memory in E3 and E4 mice relative to the AL group. Brain transcriptomics revealed that CR upregulated the cholesterol synthesis pathway, potentially improving myelination‐related pathways in E3 and E4 mice. This finding was further validated by the increased staining intensity of myelin basic protein (MBP) observed in E3 and E4 mice from an independent cohort. In contrast, these effects were not pronounced in E2 mice. Additionally, while CR’s impact on the brain lipid profile was minor across all APOE genotypes, it significantly altered blood lipid profile of E2 mice, with minimal changes observed in E3 and E4 mice. Finally, in microbiomics, CR led to notable changes in the abundance of Bifidobacterium species in E3 and E4 mice and Lactobacillus species in E2 mice.ConclusionsOur study highlights the role of APOE genotypes in modulating the diverse effects of CR on cognition, brain transcriptomics, lipid metabolism, and the microbiome, providing a crucial foundation for considering APOE genotypes in developing prevention strategies for aging and age‐related disorders.
Genotypic and phenotypic characterization of Enterococcus faecalis isolates from periprosthetic joint infections
Haeberle, Amanda L. , Greenwood‐Quaintance, Kerryl E. , Zar, Sarah, Patel, Robin , Willett, Julia L. E. , Patel, Robin , Willett, Julia L E , Greenwood-Quaintance, Kerryl , Johnson, Stephen A.

Mayo Clinic

Microbiology Spectrum | June 24, 2024 | Volume: 12 | Issue: 8 | Pages: No page available

10.1128/spectrum.00565-24 | PMID 38912797 Get It

ABSTRACT Over 2.5 million prosthetic joint implantation surgeries occur annually in the United States. Periprosthetic joint infections (PJIs), though occurring in only 1–2% of patients receiving replacement joints, are challenging to diagnose and treat and are associated with significant morbidity. The Gram-positive bacterium Enterococcus faecalis , which can be highly antibiotic-resistant and is a robust biofilm producer on indwelling medical devices, accounts for 2–11% of PJIs. E. faecalis PJIs are understudied compared to those caused by other pathogens, such as Staphylococcus aureus . This motivates the need to generate a comprehensive understanding of E. faecalis PJIs to guide future treatments for these infections. To address this, we describe a panel of E. faecalis strains isolated from the surface of prosthetic joints in a cohort of individuals treated at the Mayo Clinic in Rochester, MN. Here, we present the first complete genome assemblage of E. faecalis PJI isolates. Comparative genomics shows differences in genome size, virulence factors, antimicrobial resistance genes, plasmids, and prophages, underscoring the genetic diversity of these strains. These isolates have strain-specific differences in in vitro biofilm biomass, biofilm burden, and biofilm morphology. We measured robust changes in biofilm architecture and aggregation for all isolates when grown in simulated synovial fluid (SSF). Finally, we evaluated the antibiotic efficacy of these isolates and found strain-specific changes across all strains when grown in SSF. Results of this study highlight the existence of genetic and phenotypic heterogeneity among E. faecalis PJI isolates which will provide valuable insight and resources for future E. faecalis PJI research. IMPORTANCE Periprosthetic joint infections (PJIs) affect ~1–2% of those who undergo joint replacement surgery. Enterococcus faecalis is a Gram-positive opportunistic pathogen that causes ~10% of PJIs in the United States each year, but our understanding of how and why E. faecalis causes PJIs is limited. E. faecalis infections are typically biofilm-associated and can be difficult to clear with antibiotic therapy. Here, we provide complete genomes for four E. faecalis PJI isolates from the Mayo Clinic. These isolates have strain-specific differences in biofilm formation, aggregation, and antibiotic susceptibility in simulated synovial fluid. These results provide important insight into the genomic and phenotypic features of E. faecalis isolates from PJI.
The relationship of rate and pause features to the communicative participation of people living with ALS
Connaghan, Kathryn P. , Green, Jordan R. , Eshghi, Marziye , Haenssler, Abigail E. , Scheier, Zoe A. , Clark, Alison , Iyer, Amrita , Richburg, Brian , Rowe, Hannah P. , Okada, June , Johnson, Stephen A , Onnela, Jukka-Pekka , Burke, Katherine M , Berry, James D , Johnson, Stephen A. , Burke, Katherine M. , Berry, James D.

Mayo Clinic

Muscle & Nerve | June 4, 2024 | Volume: 70 | Issue: 2 | Pages: 217-225

10.1002/mus.28170 | PMID 38837773 Get It

AbstractIntroduction/AimsMany people living with amyotrophic lateral sclerosis (PALS) report restrictions in their day‐to‐day communication (communicative participation). However, little is known about which speech features contribute to these restrictions. This study evaluated the effects of common speech symptoms in PALS (reduced overall speaking rate, slowed articulation rate, and increased pausing) on communicative participation restrictions.MethodsParticipants completed surveys (the Communicative Participation Item Bank‐short form; the self‐entry version of the ALS Functional Rating Scale‐Revised) and recorded themselves reading the Bamboo Passage aloud using a smartphone app. Rate and pause measures were extracted from the recordings. The association of various demographic, clinical, self‐reported, and acoustic speech features with communicative participation was evaluated with bivariate correlations. The contribution of salient rate and pause measures to communicative participation was assessed using multiple linear regression.ResultsFifty seven people living with ALS participated in the study (mean age = 61.1 years). Acoustic and self‐report measures of speech and bulbar function were moderately to highly associated with communicative participation (Spearman rho coefficients ranged from rs = 0.48 to rs = 0.77). A regression model including participant age, sex, articulation rate, and percent pause time accounted for 57% of the variance of communicative participation ratings.DiscussionEven though PALS with slowed articulation rate and increased pausing may convey their message clearly, these speech features predict communicative participation restrictions. The identification of quantitative speech features, such as articulation rate and percent pause time, is critical to facilitating early and targeted intervention and for monitoring bulbar decline in ALS.
Tracking amyotrophic lateral sclerosis disease progression using passively collected smartphone sensor data
Karas, Marta , Olsen, Julia , Strączkiewicz, Marcin , Iwasaki, Satoshi, Lahav, Amir, Scheier, Zoe A. , Clark, Alison , Iyer, Amrita S. , Huang, Emily J. , Johnson, Stephen A. , Burke, Katherine M. , Berry, James D. , Onnela, Jukka-Pekka

Mayo Clinic

Annals of Clinical and Translational Neurology | May 31, 2024 | Volume: 11 | Issue: 6 | Pages: 1380-1392

10.1002/acn3.52050 | PMID 38816946 Get It

AbstractBackgroundPassively collected smartphone sensor data provide an opportunity to study physical activity and mobility unobtrusively over long periods of time and may enable disease monitoring in people with amyotrophic lateral sclerosis (PALS).MethodsWe enrolled 63 PALS who used Beiwe mobile application that collected their smartphone accelerometer and GPS data and administered the self‐entry ALS Functional Rating Scale‐Revised (ALSFRS‐RSE) survey. We identified individual steps from accelerometer data and used the Activity Index to summarize activity at the minute level. Walking, Activity Index, and GPS outcomes were then aggregated into day‐level measures. We used linear mixed effect models (LMMs) to estimate baseline and monthly change for ALSFRS‐RSE scores (total score, subscores Q1–3, Q4–6, Q7–9, Q10–12) and smartphone sensor data measures, as well as the associations between them.FindingsThe analytic sample (N = 45) was 64.4% male with a mean age of 60.1 years. The mean observation period was 292.3 days. The ALSFRS‐RSE total score baseline mean was 35.8 and had a monthly rate of decline of −0.48 (p‐value <0.001). We observed statistically significant change over time and association with ALSFRS‐RSE total score for four smartphone sensor data‐derived measures: walking cadence from top 1 min and log‐transformed step count, step count from top 1 min, and Activity Index from top 1 min.InterpretationSmartphone sensors can unobtrusively track physical changes in PALS, potentially aiding disease monitoring and future research.
Multi-Site Microbiome Composition in Atopic Dermatitis: A Case-Control Study
Pitlick, Mitchell M. , Johnson, Stephen , Mullakary, Roshini M. , Taneja, Veena , Joshi, Avni Y. , Taneja, Veena , Johnson, Stephen

Mayo Clinic

Annals of Dermatology | January 9, 2024 | Volume: 36 | Issue: 1 | Pages: 55

10.5021/ad.22.117 | PMID 38325434 Get It

Arteriovenous Fistula Presenting as Progressive Bifrontal Intracerebral Hemorrhage (P6.209)
Cox, Benjamin C. , Johnson, Stephen A. , Scharf, Eugene

Mayo Clinic

Neurology | December 7, 2023 | Volume: 90 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.90.15_supplement.p6.209 Get It

Caffeine Augments Anesthesia Neurotoxicity in the Fetal Macaque Brain (P5.6-065)
Masuoka, Kobe, Williams, Sasha , Martin, Lauren , Dissen, Gregory A. , Olney, John W., Brambrink, Ansgar M. , Noguchi, Kevin, Johnson, Stephen A. , Manzella, Francesca M. , Ikonomidou, Chrysanthy , Schenning, Katie J.

Mayo Clinic

Neurology | December 7, 2023 | Volume: 92 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.92.15_supplement.p5.6-065 Get It

Population Characteristics and Progression to Disability Among Patients with Small Fiber Neuropathy (2538)
Johnson, Stephen , Hoffman, E. Matthew , Staff, Nathan P. , Klein, Christopher J.

Mayo Clinic

Neurology | December 7, 2023 | Volume: 94 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.94.15_supplement.2538 Get It